Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep:37:100747.
doi: 10.1016/j.nmni.2020.100747. Epub 2020 Aug 20.

Hydroxychloroquine is protective to the heart, not harmful: a systematic review

C C Prodromos  1 , T Rumschlag  1 , T Perchyk  1
Affiliations
Review

Hydroxychloroquine is protective to the heart, not harmful: a systematic review

C C Prodromos et al. New Microbes New Infect. 2020 Sep.

Abstract

Hydroxychloroquine (HCQ) has been shown to be at least somewhat effective in treating patients with coronavirus disease 2019 (COVID-19). Recently the US Food and Drug Administration and Centers for Disease Control and Prevention warnings of fatal cardiac toxicity from torsades de pointes (TDP) arrhythmia from HCQ receipt have been made, notwithstanding the long safe provision of HCQ to treat lupus and rheumatoid arthritis. This has resulted in restricted access of HCQ for COVID-19 treatment. We hypothesized that HCQ and azithromycin have not been reported to cause significant acute cardiac arrhythmic mortality. We performed a literature search for the effects of HCQ and azithromycin on the heart. No TDP or related deaths were found to have been reported as a result of HCQ and azithromycin receipt in the peer-reviewed literature. On the contrary, HCQ and azithromycin were both found to substantially reduce cardiac mortality and also decrease thrombosis, arrhythmia and cholesterol in treated patients in recent peer-reviewed studies and meeting presentations. HCQ and azithromycin do not cause TDP cardiac mortality; rather, HCQ decreases cardiac events. HCQ should not be restricted in COVID-19 patients out of fear of cardiac mortality.

Keywords: Azithromycin; COVID-19; SARS-CoV-2; hydroxychloroquine.

PubMed Disclaimer

References

    1. Chen J., Liu D., Liu L., Liu P., Xu Q., Xia L. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19] Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49:215–219. - PMC - PubMed
    1. Million M., Lagier J.C., Gautret P., Colson P., Fournier P.E., Amrane S. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;35:101738. - PMC - PubMed
    1. Yu B., Li C., Chen P., Zhou N., Wang L., Li J. Sci China Life Sci; 2020. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. - PMC - PubMed
    1. Olding R., Cartwright L. 22 May 2020. Controversial doc in Trump’s ear calls malaria drug study ‘garbage.’ Daily Beast.https://www.thedailybeast.com/vladimir-zelenko-controversial-doc-in-trum... Available at:
    1. Alia E., Grant-Kels J.M. Does hydroxychloroquine combat COVID-19? A timeline of evidence. J Am Acad Dermatol. 2020;83:e33–e34. - PMC - PubMed